Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 1/2018

01-01-2018 | Review Article

Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages

Authors: Gábor Holló, Andreas Katsanos, Kostas G. Boboridis, Murat Irkec, Anastasios G. P. Konstas

Published in: Drugs | Issue 1/2018

Login to get access

Abstract

Glaucoma therapy-related ocular surface disease (OSD) is a serious pathology with a broad spectrum of insidious clinical presentations and complex pathogenesis that undermines long-term glaucoma care. Preservatives, especially benzalkonium chloride (BAK), contained in topical intraocular pressure-lowering medications frequently cause or aggravate OSD in glaucoma. Management of these patients is challenging, and to date often empirical due to the scarcity of controlled long-term clinical trials. Most of the available data are extracted from case series and retrospective analysis. Preservative-free prostaglandins and prostaglandin/timolol fixed combinations are novel options developed to remove the harmful impact of preservatives, especially BAK, upon ocular tissues. Based on what is currently known on the value of preservative-free antiglaucoma therapies it is tempting to speculate how these new therapies may affect the future medical management of all glaucoma patients. This article provides a comprehensive and critical review of the current literature on preservative-free prostaglandins and preservative-free prostaglandin/timolol fixed combinations.
Literature
1.
2.
Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295–304.PubMedCrossRef
3.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.PubMedCrossRef
4.
European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: PubliComm; 2014.
5.
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13 (discussion 829–30).PubMedCrossRef
6.
7.
Topouzis F, Harris A, Wilson MR, Koskosas A, Founti P, Yu F, et al. Increased likelihood of glaucoma at the same screening intraocular pressure in subjects with pseudoexfoliation: the Thessaloniki Eye Study. Am J Ophthalmol. 2009;148(606–13):e1.
8.
Teus MA, Castejón MA, Calvo MA, Pérez-Salaíces P, Marcos A. Intraocular pressure as a risk factor for visual field loss in pseudoexfoliative and in primary open-angle glaucoma. Ophthalmology. 1998;105:2225–9 (discussion 2229–30).PubMedCrossRef
9.
Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61–9.PubMedCrossRef
10.
Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–8.PubMedCrossRef
11.
Konstas AG, Maskaleris G, Gratsonidis S, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye (London). 2000;14(Pt 5):752–6.CrossRef
12.
Olthoff CMG, Schouten JSAG, van de Borne BW, Webers CAB. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953–61.PubMedCrossRef
13.
Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737–47.PubMedCrossRef
14.
Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618–21.PubMedCrossRef
15.
Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch. Clin. Exp. Ophthalmol. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593–601.PubMedCrossRef
16.
Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–9.PubMed
17.
18.
Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446–54.PubMedCrossRef
19.
Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108:1543–8.PubMedCrossRef
20.
Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730–5.PubMedCrossRef
21.
Hommer A. Role of fixed combinations in the management of open-angle glaucoma. Expert Rev Pharmacoecon Outcomes Res. 2011;11:91–9.PubMedCrossRef
22.
Konstas A, Quaranta L, Katsanos A, Voudouragkaki I, Dutton G. Fixed combination therapies in glaucoma. In: Shaarawy T, Sherwood M, Hitchings R, Crowston J, editors. glaucoma. 2nd ed. Elsevier: London; 2015. p. 583–92.CrossRef
23.
Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53(Suppl 1):S69–84.PubMedCrossRef
24.
van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177–85.PubMedCrossRef
25.
Konstas AGP, Katsanos A, Quaranta L, Mikropoulos DG, Tranos PG, Teus MA. Twenty-four hour efficacy of glaucoma medications. Prog Brain Res. 2015;221:297–318.PubMedCrossRef
26.
Konstas AGP, Quaranta L, Bozkurt B, Katsanos A, Garcia-Feijoo J, Rossetti L, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016;33:481–517.PubMedPubMedCentralCrossRef
27.
Stewart WC, Konstas AGP, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115(1117–22):e1.
28.
29.
Sousa DC, Leal I, Nascimento N, Marques-Neves C, Tuulonen A, Abegão Pinto L. Use of ocular hypotensive medications in Portugal: PEM study: a cross-sectional nationwide analysis. J Glaucoma. 2017;26:571–6.PubMedCrossRef
30.
Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29:382–9.PubMedCrossRef
31.
Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667–73.PubMedCrossRef
32.
Stewart WC, Konstas AGP, Kruft B, Mathis HM, Stewart JA. Meta-analysis of 24-h intraocular pressure fluctuation studies and the efficacy of glaucoma medicines. J Ocul Pharmacol Ther. 2010;26:175–80.PubMedCrossRef
33.
Riva I, Katsanos A, Floriani I, Biagioli E, Konstas AGP, Centofanti M, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J. Glaucoma. 2014;23:535–40.PubMedCrossRef
34.
Friström B, Uusitalo H. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Acta Ophthalmol (Copenh). 2010;88:37–43.CrossRef
35.
Watson PG. Latanoprost. Two years’ experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82–7.PubMedCrossRef
36.
Alm A, Widengård I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000;78:71–6.PubMedCrossRef
37.
Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12:232–6.PubMedCrossRef
38.
Quaranta L, Katsanos A, Russo A, Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58:26–41.PubMedCrossRef
39.
Konstas AGP, Quaranta L, Mikropoulos DG, Nasr MB, Russo A, Jaffee HA, et al. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012;28:26–32.PubMedCrossRef
40.
Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther. 2000;22:167–208.PubMedCrossRef
41.
Lin L, Zhao YJ, Chew PTK, Sng CCA, Wong H-T, Yip LW, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014;48:1585–93.PubMedCrossRef
42.
Konstas AG, Mantziris DA, Maltezos A, Cate EA, Stewart WC. Comparison of 24 hour control with Timoptic 0.5% and Timoptic-XE 0.5% in exfoliation and primary open-angle glaucoma. Acta Ophthalmol Scand. 1999;77:541–3.PubMedCrossRef
43.
Quaranta L, Katsanos A, Floriani I, Riva I, Russo A, Konstas AGP. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52:1552–7.PubMedCrossRef
44.
Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132–5.PubMedCrossRef
45.
Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011;27:1949–58.PubMedCrossRef
46.
Konstas AGP, Haidich A-B, Rossetti L, Webers C. Prostaglandin-timolol fixed combinations efficacy: myth or reality? Eur J Ophthalmol. 2012;22:1–4.PubMedCrossRef
47.
Konstas AG, Mocan MC, Katsanos A, Voudouragkaki IC, Irkec M. Latanoprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Pharmacother. 2013;14:1815–27.PubMedCrossRef
48.
Shah B, Arora V, Wadhwani M, Mishra S. Prostaglandin analogs. J Curr Glaucoma Pract. 2011;5:15–20.CrossRef
49.
Camras C, Toris C. Advances in glaucoma management: risk factors, diagnostic tools, therapies and the role of prostaglandin analogs. Foreword Surv Ophthalmol. 2008;53(Suppl 1):S1–2.PubMed
50.
51.
Dams I, Wasyluk J, Prost M, Kutner A. Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies. Prostaglandins Other Lipid Mediat. 2013;104–5:109–21.CrossRef
52.
Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43:1475–87.PubMed
53.
Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci. 1977;16:1125–34.PubMed
54.
Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53(Suppl 1):S107–20.PubMedPubMedCentralCrossRef
55.
Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002;18:313–24.PubMedCrossRef
56.
Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin Investig Drugs. 2001;10:721–31.PubMedCrossRef
57.
Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179–91.PubMedCrossRef
58.
Kim JW, Lindsey JD, Wang N, Weinreb RN. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci. 2001;42:1514–21.PubMed
59.
Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36:2461–5.PubMed
60.
Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13:723–45.PubMedCrossRef
61.
Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost : an update of its use in glaucoma and ocular hypertension. Drugs Aging. 2003;20:597–630.PubMedCrossRef
62.
Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41(Suppl 2):S105–10.PubMedCrossRef
63.
Konstas AGP, Mylopoulos N, Karabatsas CH, Kozobolis VP, Diafas S, Papapanos P, et al. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye (London). 2004;18:893–9.CrossRef
64.
Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–52.PubMedCrossRef
65.
Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138–47.PubMedCrossRef
66.
Rácz P, Ruzsonyi MR, Nagy ZT, Gaygi Z, Bito LZ. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114:268–73.PubMedCrossRef
67.
Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AGP. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clin Ophthalmol. 2015;9:633–43.PubMedPubMedCentralCrossRef
68.
Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472–84.PubMedCrossRef
69.
Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK, et al. Comparison of topical travoprost eyedrops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10:414–22.PubMedCrossRef
70.
Li N, Chen X, Zhou Y, Wei M, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Exp Ophthalmol. 2006;34:755–64.PubMedCrossRef
71.
Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002;19:231–48.PubMedCrossRef
72.
Swymer C, Neville MW. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2012;46:1506–10.PubMedCrossRef
73.
Eyawo O, Nachega J, Lefebvre P, Meyer D, Rachlis B, Lee C-W, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447–56.PubMedPubMedCentral
74.
Konstas AGP, Quaranta L, Katsanos A, Riva I, Tsai JC, Giannopoulos T, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97:1510–5.PubMedCrossRef
75.
Schnober D, Hofmann G, Maier H, Scherzer M-L, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;4:1459–63.PubMedPubMedCentralCrossRef
76.
Wu N, Chen Y, Yu X, Li M, Wen W, Sun X. Changes in corneal biomechanical properties after long-term topical prostaglandin therapy. PLoS One. 2016;11:e0155527.PubMedPubMedCentralCrossRef
77.
Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57–68.PubMedCrossRef
78.
Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–8.PubMedCrossRef
79.
Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–40.PubMedCrossRef
80.
Campbell JH, Schwartz GF, LaBounty B, Kowalski JW, Patel VD. Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. Clin Ophthalmol. 2014;8:927–35.PubMedPubMedCentralCrossRef
81.
Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47(Suppl 1):S219.PubMedCrossRef
82.
83.
Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93–105.PubMedCrossRef
84.
Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135:314–20.PubMedCrossRef
85.
Cracknell KPB, Grierson I. Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Exp Eye Res. 2009;88:786–91.PubMedCrossRef
86.
Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2012;153:1187–96.PubMedCrossRef
87.
Tan P, Malhotra R. Oculoplastic considerations in patients with glaucoma. Surv Ophthalmol. 2016;61:718–25.PubMedCrossRef
88.
Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22:626–31.PubMedCrossRef
89.
Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. J Glaucoma. 2016;25:770–4.PubMedCrossRef
90.
Pflugfelder SC, Baudouin C. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol. 2011;5:1575–83.PubMedPubMedCentral
91.
Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246–58.PubMedCrossRef
92.
The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf. 2007;5:75–92.
93.
Hansen EW. Mucocutaneous eruptions, including conjunctiva, due to drug sensitivity; etiological similarity to pemphigus. Trans Am Ophthalmol Soc. 1950;48:395–421.PubMedCentral
94.
95.
Baudouin C, Renard J-P, Nordmann J-P, Denis P, Lachkar Y, Sellem E, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23:47–54.CrossRef
96.
Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–5.PubMedCrossRef
97.
Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–23.PubMedPubMedCentralCrossRef
98.
Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009;127:763–8.PubMedPubMedCentralCrossRef
99.
Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1–9):e2.
100.
Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma. 2001;10:483–6.PubMedCrossRef
101.
Champeau E, Edelhauser H. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: Holly F, Lamberts D, MacKeen D, editors. The preocular tear film in health, disease and contact lens wear. Lubbock: Dry Eye Institute; 1986. p. 292–302.
102.
Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27:837–45.PubMedCrossRef
103.
Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A, 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19:37–44.PubMedCrossRef
104.
Labbé A, Pauly A, Liang H, Brignole-Baudouin F, Martin C, Warnet J-M, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006;22:267–78.PubMedCrossRef
105.
Ayaki M, Iwasawa A. Cytotoxicity of prostaglandin analog eyedrops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. Clin Ophthalmol. 2010;4:919–24.PubMedPubMedCentralCrossRef
106.
Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99:1082–8.PubMedCrossRef
107.
Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96:327–35.PubMedCrossRef
108.
Shimazaki J, Hanada K, Yagi Y, Yamagami J, Ishioka M, Shimmura S, et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone. Br J Ophthalmol. 2000;84:1250–4.PubMedPubMedCentralCrossRef
109.
Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17:584–9.PubMedCrossRef
110.
Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643–51.PubMedCrossRef
111.
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.PubMedCrossRef
112.
Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300–6.PubMedPubMedCentralCrossRef
113.
Geerling G, Baudouin C, Aragona P, Rolando M, Boboridis KG, Benítez-Del-Castillo JM, et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: proceedings of the OCEAN group meeting. Ocul Surf. 2017;15:179–92.PubMedCrossRef
114.
Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28:93–103.PubMedCrossRef
115.
Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5:459–63.PubMedCrossRef
116.
Yalvaç IS, Gedikoğlu G, Karagöz Y, Akgün U, Nurözler A, Koç F, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246–8.PubMedCrossRef
117.
Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339–43.PubMedCrossRef
118.
Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25:743–51.PubMedCrossRef
119.
Mackie IA, Seal DV, Pescod JM. Beta-adrenergic receptor blocking drugs: tear lysozyme and immunological screening for adverse reaction. Br J Ophthalmol. 1977;61:354–9.PubMedPubMedCentralCrossRef
120.
Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12:486–90.PubMedCrossRef
121.
Labbé A, Terry O, Brasnu E, Van Went C, Baudouin C. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31:994–9.PubMedCrossRef
122.
Rossi GCM, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572–9.PubMed
123.
Martone G, Frezzotti P, Tosi GM, Traversi C, Mittica V, Malandrini A, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147(725–735):e1.
124.
Pauly A, Meloni M, Brignole-Baudouin F, Warnet J-M, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009;50:1644–52.PubMedCrossRef
125.
126.
De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619–30.
127.
Williams DE, Nguyen KD, Shapourifar-Tehrani S, Kitada S, Lee DA. Effects of timolol, betaxolol, and levobunolol on human tenon’s fibroblasts in tissue culture. Invest Ophthalmol Vis Sci. 1992;33:2233–41.PubMed
128.
Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol (Copenh). 2008;86:716–26.CrossRef
129.
Broadway D, Hitchings R, Grierson I. Topical antiglaucomatous therapy: adverse effects on the conjunctiva and implications for filtration surgery. J Glaucoma. 1995;4:136.PubMedCrossRef
130.
Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992;99:197–202.PubMedCrossRef
131.
Kashkouli MB, Pakdel F, Hashemi M, Ghaempanah MJ, Rezaee R, Kaghaz-Kanani R, et al. Comparing anatomical pattern of topical anti-glaucoma medications associated lacrimal obstruction with a control group. Orbit. 2010;29:65–9.PubMedCrossRef
132.
Hamard P, Blondin C, Debbasch C, Warnet J-M, Baudouin C, Brignole F. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003;241:1037–43.PubMedCrossRef
133.
Samples JR, Binder PS, Nayak S. The effect of epinephrine and benzalkonium chloride on cultured corneal endothelial and trabecular meshwork cells. Exp Eye Res. 1989;49:1–12.PubMedCrossRef
134.
Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011;17:1806–13.PubMedPubMedCentral
135.
Bouchemi M, Roubeix C, Kessal K, Riancho L, Raveu A-L, Soualmia H, et al. Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma. Toxicol In Vitro. 2017;41:21–9.PubMedCrossRef
136.
Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437–45.PubMedCrossRef
137.
Pisella P-J, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360–8.PubMedCrossRef
138.
Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111:2186–92.PubMedCrossRef
139.
Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet J-M, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109–15.PubMedCrossRef
140.
Leonardi A, Van Setten G, Amrane M, Ismail D, Garrigue J-S, Figueiredo FC, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26:287–96.PubMedCrossRef
141.
Baudouin C, Figueiredo FC, Messmer EM, Ismail D, Amrane M, Garrigue J-S, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017. https://​doi.​org/​10.​5301/​ejo.​5001002 (Epub ahead of print).
142.
Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145–52.PubMedCrossRef
143.
Konstas AGP, Holló G. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma. Expert Opin Pharmacother. 2016;17:1271–83.PubMedCrossRef
144.
Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–34.PubMedCrossRef
145.
Stalmans I, Sunaric Mégevand G, Cordeiro MF, Hommer A, Rossetti L, Goñi F, et al. Preservative-free treatment in glaucoma: who, when, and why. Eur J Ophthalmol. 2013;23:518–25.PubMedCrossRef
146.
Konstas A-G, Boboridis KG, Kapis P, Marinopoulos K, Voudouragkaki IC, Panayiotou D, et al. 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017;34:221–35.PubMedCrossRef
147.
Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma. 2001;10:237–49.PubMedCrossRef
148.
149.
Fogagnolo P, Rossetti L. Medical treatment of glaucoma: present and future. Expert Opin Investig Drugs. 2011;20:947–59.PubMedCrossRef
150.
Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36:391–8.PubMedCrossRef
151.
de Jong C, Stolwijk T, Kuppens E, de Keizer R, van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232:221–4.PubMedCrossRef
152.
Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res. 2009;41:118–22.PubMedCrossRef
153.
Denis P, Demailly P, Saraux H. Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension. J Fr Ophtalmol. 1993;16:297–303.PubMed
154.
Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39–42.PubMedPubMedCentralCrossRef
155.
Easty DL, Nemeth-Wasmer G, Vounatsos J-P, Girard B, Besnainou N, Pouliquen P, et al. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol. 2006;90:574–8.PubMedPubMedCentralCrossRef
156.
Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl. 2008;242:14–9.CrossRef
157.
Shedden A, Adamsons IA, Getson AJ, Laurence JK, Lines CR, Hewitt DJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPTTM) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;248:1757–64.PubMedCrossRef
158.
Iester M, Telani S, Frezzotti P, Motolese I, Figus M, Fogagnolo P, et al. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J Ocul Pharmacol Ther. 2014;30:476–81.PubMedCrossRef
159.
Goldberg I, Gil Pina R, Lanzagorta-Aresti A, Schiffman RM, Liu C, Bejanian M. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014;98:926–31.PubMedPubMedCentralCrossRef
160.
Narayanaswamy A, Neog A, Baskaran M, George R, Lingam V, Desai C, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55:127–31.PubMedCrossRef
161.
Kahook MY, Fechtner RD, Katz LJ, Noecker RJ, Ammar DA. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res. 2012;37:101–8.PubMedCrossRef
162.
Macdonald ECA, Lockington D, Roberts F, Tetley L, Ramaesh K. Unit-dose dispenser tips: a potential source of ocular injury. Br J Ophthalmol. 2010;94:136–7.PubMedCrossRef
163.
Dietlein TS, Jordan JF, Lüke C, Schild A, Dinslage S, Krieglstein GK. Self-application of single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmol (Copenh). 2008;86:856–9.CrossRef
164.
Uusitalo H, Pillunat LE, Ropo A, Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eyedrops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol (Copenh). 2010;88:12–9.CrossRef
165.
Day DG, Walters TR, Schwartz GF, Mundorf TK, Liu C, Schiffman RM, et al. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013;97:989–93.PubMedPubMedCentralCrossRef
166.
Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016;254:1151–8.PubMedCrossRef
167.
Parkkari M, Latvala T, Ropo A. Handling test of eyedrop dispenser–comparison of unit-dose pipettes with conventional eyedrop bottles. J Ocul Pharmacol Ther. 2010;26:273–6.PubMedPubMedCentralCrossRef
168.
Denis P, Monoprost French Study Group. Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study. J Fr Ophtalmol. 2016;39:622–30.PubMedCrossRef
169.
Daull P, Buggage R, Lambert G, Faure M-O, Serle J, Wang R-F, et al. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models. J Ocul Pharmacol Ther. 2012;28:515–23.PubMedCrossRef
170.
Sanford M. Preservative-free latanoprost eyedrops in patients with primary open-angle glaucoma/ocular hypertension. Clin Drug Investig. 2014;34:521–8.PubMedCrossRef
171.
Rouland J-F, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, et al. Efficacy and safety of preservative-free latanoprost eyed rops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97:196–200.PubMedCrossRef
172.
Cucherat M, Stalmans I, Rouland J-F. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014;23:e69–75.PubMedCrossRef
173.
Muñoz Negrete FJ, Lemij HG, Erb C. Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol. 2017;11:557–66.PubMedPubMedCentralCrossRef
174.
175.
Smedowski A, Paterno JJ, Toropainen E, Sinha D, Wylegala E, Kaarniranta K. Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. J Biochem Pharmacol Res. 2014;2:175–84.PubMedPubMedCentral
176.
Trzeciecka A, Paterno JJ, Toropainen E, Koskela A, Podracka L, Korhonen E, et al. Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. Eur J Pharmacol. 2016;788:12–20.PubMedCrossRef
177.
Esaki Y, Shimazaki A, Pellinen P. Ocular tolerability of preservative-free tafluprost and latanoprost: in vitro and in vivo comparative study. Open Ophthalmol J. 2016;10:146–53.PubMedPubMedCentralCrossRef
178.
Pillunat LE, Eschstruth P, Häsemeyer S, Thelen U, Foja C, Leaback R, et al. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clin Ophthalmol. 2016;10:1759–65.PubMedPubMedCentralCrossRef
179.
Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–76.PubMedCrossRef
180.
Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY. Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011;28:707–15.PubMedCrossRef
181.
Liang H, Pauly A, Riancho L, Baudouin C, Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol. 2011;95:869–75.PubMedPubMedCentralCrossRef
182.
Rossi GCM, Blini M, Scudeller L, Ricciardelli G, Depolo L, Amisano A, et al. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group. J Ocul Pharmacol Ther. 2013;29:821–5.PubMedCrossRef
183.
Rolle T, Spinetta R, Nuzzi R. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study. BMC Ophthalmol. 2017;17:136.PubMedPubMedCentralCrossRef
184.
185.
Rossi GCM, Pasinetti GM, Raimondi M, Ricciardelli G, Scudeller L, Blini M, et al. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients. Expert Opin Drug Saf. 2012;11:519–25.PubMedCrossRef
186.
Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol (Copenh). 2010;88:329–36.CrossRef
187.
Erb C, Lanzl I, Seidova S-F, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther. 2011;28:575–85.PubMedCrossRef
188.
Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26:1905–13.PubMedCrossRef
189.
Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clin Ophthalmol. 2011;5:623–31.PubMedPubMedCentral
190.
Milla E, Stirbu O, Rey A, Duch S, Buchacra O, Robles A, et al. Spanish multicenter tafluprost tolerability study. Br J Ophthalmol. 2012;96:826–31.PubMedCrossRef
191.
Janulevičienė I, Derkač I, Grybauskiene L, Paulauskaitė R, Gromnickaite R, Kuzmienė L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol. 2012;6:103–9.PubMedPubMedCentralCrossRef
192.
Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26:97–104.PubMedCrossRef
193.
Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. Benefits of switching from latanoprost to preservative-free tafluprost eyedrops: a meta-analysis of two phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–54.PubMedPubMedCentralCrossRef
194.
Mochizuki H, Itakura H, Yokoyama T, Takamatsu M, Kiuchi Y. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Jpn J Ophthalmol. 2010;54:286–90.PubMedCrossRef
195.
Katsanos A, Dastiridou AI, Fanariotis M, Kotoula M, Tsironi EE. Bimatoprost and bimatoprost/timolol fixed combination in patients with open-angle glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2011;27:67–71.PubMedCrossRef
196.
Holló G, Hommer A, Antón López A, Ropo A. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30:468–75.PubMedCrossRef
197.
Kaarniranta K, Ikäheimo K, Mannermaa E, Ropo A. Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a phase I comparison vs. the corresponding preservative-free monotherapies. Clin Pharmacokinet. 2016;55:485–94.PubMedCrossRef
198.
Holló G, Vuorinen J, Tuominen J, Huttunen T, Ropo A, Pfeiffer N. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31:932–44.PubMedPubMedCentralCrossRef
199.
Seibold LK, DeWitt PE, Kroehl ME, Kahook MY. The 24-hour effects of brinzolamide/brimonidine fixed combination and timolol on intraocular pressure and ocular perfusion pressure. J Ocul Pharmacol Ther. 2017;33:161–9.PubMedCrossRef
200.
201.
Mäenpää J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016;15:1549–61.PubMedCrossRef
202.
Holló G, Katsanos A. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Drug Saf. 2015;14:609–17.PubMedCrossRef
203.
Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Mäenpää J, Pelkonen O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos. 2007;35:1135–41.PubMedCrossRef
204.
Okabe K, Kimura H, Okabe J, Kato A, Shimizu H, Ueda T, et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2005;46:703–8.PubMedCrossRef
205.
Shen J, Bejanian M. Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon. Clin Ophthalmol. 2016;10:373–83.PubMedPubMedCentralCrossRef
206.
Fuwa M, Ueda K, Akaishi T, Yamashita N, Kirihara T, Shimazaki A, et al. Advantages of efficacy and safety of fixed-dose tafluprost/timolol combination over fixed-dose latanoprost/timolol combination. PLoS One. 2016;11:e0158797.PubMedPubMedCentralCrossRef
207.
Pfeiffer N, Traverso CE, Lorenz K, Saarela V, Liinamaa J, Uusitalo H, et al. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014;31:1228–46.PubMedPubMedCentralCrossRef
208.
Akaishi T, Shimazaki A, Tonouchi A, Ueda K, Miyawaki N, Kawazu K. Benefits of tafluprost and timolol fixed-dose combination for the treatment of glaucoma are confirmed by studies on experimental animal models. J Ocul Pharmacol Ther. 2015;31:518–24.PubMedCrossRef
209.
Hoy SM. Tafluprost/timolol: a review in open-angle glaucoma or ocular hypertension. Drugs. 2015;75:1807–13.PubMedCrossRef
210.
Lorenz K, Pfeiffer N. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opin Pharmacother. 2014;15:2255–62.PubMedCrossRef
211.
Holló G, Ropo A. Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma. Curr Med Res Opin. 2015;31:13–6.PubMedCrossRef
212.
Takagi Y, Osaki H, Yamashita T, Kai Y. Prospective observational post-marketing study of tafluprost 0.0015%/timolol 0.5% combination ophthalmic solution for glaucoma and ocular hypertension: short-term efficacy and safety. Ophthalmol Ther. 2016;5:191–206.PubMedPubMedCentralCrossRef
213.
Ayaki M, Iwasawa A, Niwano Y. Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops. Biocontrol Sci. 2012;17:121–8.PubMedCrossRef
214.
Cordeiro MF, Goldberg I, Schiffman R, Bernstein P, Bejanian M. Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients. Clin Ophthalmol. 2015;9:1605–11.PubMedPubMedCentralCrossRef
215.
Pfennigsdorf S, Eschstruth P, Häsemeyer S, Feuerhake C, Brief G, Grobeiu I, et al. Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice. Clin Ophthalmol. 2016;10:1837–46.PubMedPubMedCentralCrossRef
Metadata
Title
Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages
Authors
Gábor Holló
Andreas Katsanos
Kostas G. Boboridis
Murat Irkec
Anastasios G. P. Konstas
Publication date
01-01-2018
Publisher
Springer International Publishing
Published in
Drugs / Issue 1/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0843-9

Other articles of this Issue 1/2018

Drugs 1/2018 Go to the issue

AdisInsight Report

Acalabrutinib: First Global Approval

Adis Drug Evaluation

Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy

Adis Drug Evaluation

Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis

Systematic Review

Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

AdisInsight Report

Letermovir: First Global Approval

Correction

Correction to: Opicapone: A Review in Parkinson’s Disease